Tags

Type your tag names separated by a space and hit enter

Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma.
J Pharm Biomed Anal. 2009 Nov 01; 50(4):640-8.JP

Abstract

Multicriteria optimization methodology was applied for development of isocratic reversed-phased HPLC method for simultaneous determination of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) in human urine and plasma. In the first stage of method development, pH value of the water phase, percentage of acetonitrile, temperature of the column and flow rate of the mobile phase were investigated using fractional factorial design. Afterwards, the optimal conditions were found employing central composite design and Derringer's desirability function. Two goals were considered, the retention factor of the MPAG to be in the range, between 0.8 and 1.118 which allowed well separation of MPAG from the urine and plasma peaks, and the shortest possible total analysis run time. Then, the obtained sigmoid functions were used to transform the optimization criteria into the desirability values. The satisfactory chromatographic conditions were obtained with mobile phase consisted of acetonitrile-phosphate buffer (pH 2.4; 0.04 M KH(2)PO(4)) (28:72, v/v). The separation was performed on C(18) Chromolith column (100 mm x 4.6 mm) with flow rate of 5 mL/min, the temperature of the column was 25 degrees C and the chosen wavelength for simultaneous determination of MPA and MPAG was 215 nm. The MPAG eluted at 0.552 min and the duration of run was 3.092 min. Afterwards, the method was subjected to validation. Linearity was observed over the concentration range of 1-50 microg/mL for MPA and 1-500 microg/mL for MPAG in urine and 1-60 microg/mL for MPA and 1-70 microg/mL for MPAG in plasma matrix. The method showed intra-day and inter-day precision with relative standard deviation lower then 5% and accuracy as recovery (%) between 100+/-5%.

Authors+Show Affiliations

Institute of Pharmaceutical Chemistry and Drug analysis, Faculty of Pharmacy, Vojvode Stepe 450, P.O. Box 146, 11000 Belgrade, Serbia. ljzivan@pharmacy.bg.ac.yuNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Validation Study

Language

eng

PubMed ID

19036547

Citation

Zivanović, Ljiljana, et al. "Multicriteria Optimization Methodology in Development of HPLC Separation of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Urine and Plasma." Journal of Pharmaceutical and Biomedical Analysis, vol. 50, no. 4, 2009, pp. 640-8.
Zivanović L, Protić A, Zecević M, et al. Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. J Pharm Biomed Anal. 2009;50(4):640-8.
Zivanović, L., Protić, A., Zecević, M., Jocić, B., & Kostić, M. (2009). Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. Journal of Pharmaceutical and Biomedical Analysis, 50(4), 640-8. https://doi.org/10.1016/j.jpba.2008.09.052
Zivanović L, et al. Multicriteria Optimization Methodology in Development of HPLC Separation of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Urine and Plasma. J Pharm Biomed Anal. 2009 Nov 1;50(4):640-8. PubMed PMID: 19036547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. AU - Zivanović,Ljiljana, AU - Protić,Ana, AU - Zecević,Mira, AU - Jocić,Biljana, AU - Kostić,Mirjana, Y1 - 2008/10/17/ PY - 2008/07/09/received PY - 2008/09/29/revised PY - 2008/09/30/accepted PY - 2008/11/28/pubmed PY - 2009/12/16/medline PY - 2008/11/28/entrez SP - 640 EP - 8 JF - Journal of pharmaceutical and biomedical analysis JO - J Pharm Biomed Anal VL - 50 IS - 4 N2 - Multicriteria optimization methodology was applied for development of isocratic reversed-phased HPLC method for simultaneous determination of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) in human urine and plasma. In the first stage of method development, pH value of the water phase, percentage of acetonitrile, temperature of the column and flow rate of the mobile phase were investigated using fractional factorial design. Afterwards, the optimal conditions were found employing central composite design and Derringer's desirability function. Two goals were considered, the retention factor of the MPAG to be in the range, between 0.8 and 1.118 which allowed well separation of MPAG from the urine and plasma peaks, and the shortest possible total analysis run time. Then, the obtained sigmoid functions were used to transform the optimization criteria into the desirability values. The satisfactory chromatographic conditions were obtained with mobile phase consisted of acetonitrile-phosphate buffer (pH 2.4; 0.04 M KH(2)PO(4)) (28:72, v/v). The separation was performed on C(18) Chromolith column (100 mm x 4.6 mm) with flow rate of 5 mL/min, the temperature of the column was 25 degrees C and the chosen wavelength for simultaneous determination of MPA and MPAG was 215 nm. The MPAG eluted at 0.552 min and the duration of run was 3.092 min. Afterwards, the method was subjected to validation. Linearity was observed over the concentration range of 1-50 microg/mL for MPA and 1-500 microg/mL for MPAG in urine and 1-60 microg/mL for MPA and 1-70 microg/mL for MPAG in plasma matrix. The method showed intra-day and inter-day precision with relative standard deviation lower then 5% and accuracy as recovery (%) between 100+/-5%. SN - 1873-264X UR - https://www.unboundmedicine.com/medline/citation/19036547/Multicriteria_optimization_methodology_in_development_of_HPLC_separation_of_mycophenolic_acid_and_mycophenolic_acid_glucuronide_in_human_urine_and_plasma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0731-7085(08)00555-4 DB - PRIME DP - Unbound Medicine ER -